Previous 10 | Next 10 |
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Confere...
Oncternal Therapeutics (ONCT) added ~9.3% in the premarket after the company disclosed updated interim results from a Phase 1/2 clinical trial evaluating TK216 in patients with relapsed or refractory Ewing sarcoma.The data is contained in an abstract that will be part of a...
Virgin Galactic Holdings (SPCE) +21% after test flight scheduled for May 22VistaGen Therapeutics (VTGN) +15% after Baird calls stock 'significantly undervalued'.Allogene Therapeutics (ALLO) +13% on positive early-stage data for CAR T candidates in blood cancer.PDS Biotechnology...
Latest data from study TK216-01 remain encouraging, are consistent with previous results, and are updated over data contained in ASCO Abstract #11500 released today Two patients who achieved a complete response (CR) remain with no evidence of disease, one for over 24 months and ...
Latest data from the CIRLL study to be presented at ASCO 2021 remain encouraging, demonstrate good, continued enrollment, are consistent with previous results and are updated over data contained in abstract #7556 released today Objective response rate (ORR) of 83% (15 of 18 eval...
Oncternal Therapeutics (ONCT) has named Salim Yazji as its new chief medical officer ("CMO").He replaces acting CMO Edwina Baskin-Bey.Yazji founded Elpida Therapeutics in January 2019 and co-founded Ajuta Therapeutics.Oncternal shares closed up 6.4% to $5.30. For further details s...
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of industry veteran Salim Yazji, M.D., as Chief Medical Officer. ...
Image source: The Motley Fool. Oncternal Therapeutics, Inc. (NASDAQ: ONCT) Q1 2021 Earnings Call May 06, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Oncternal Therapeutics, Inc. (ONCT) Q1 2021 Earnings Call Tran...
Oncternal Therapeutics, Inc. (ONCT) Q1 2021 Earnings Conference Call May 06, 2021, 05:00 PM ET Company Participants Richard Vincent - Chief Financial Officer Jim Breitmeyer - President & Chief Executive Officer Edwina Baskin-Bey - Acting Chief Medical Officer Conference Call Participants ...
Oncternal Therapeutics (ONCT): Q1 GAAP EPS of -$0.12 misses by $0.02.Revenue of $0.75M (+29.3% Y/Y) misses by $0.36M.As of March 31, 2021, we had $111.2 million in cash and cash equivalents. We believe these funds will be sufficient to fund our operations into 2023. As of March 31, 2021, we h...
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NASDAQ Market:
Oncternal Therapeutics Inc. Website:
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2024 financial results after the U.S. financial markets c...
2024-07-26 13:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Pha...